HC Wainwright Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $60.00

Kymera Therapeutics (NASDAQ:KYMR) had its target price upped by investment analysts at HC Wainwright from $54.00 to $60.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 91.39% from the company’s current price. HC Wainwright also issued estimates for Kymera Therapeutics’ Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.75) EPS and FY2029 earnings at ($0.57) EPS.

KYMR has been the topic of several other research reports. UBS Group dropped their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. BTIG Research began coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 target price on the stock. Guggenheim boosted their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, November 1st. Morgan Stanley upped their price objective on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Wednesday, November 6th. Finally, Leerink Partners reissued an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $56.69.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR opened at $31.35 on Friday. The firm has a market cap of $2.03 billion, a PE ratio of -13.40 and a beta of 2.18. Kymera Therapeutics has a 52 week low of $29.16 and a 52 week high of $53.27. The firm’s fifty day moving average is $39.02 and its 200-day moving average is $43.74.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The firm had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Sell-side analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Buying and Selling

In related news, insider Ellen Chiniara sold 3,129 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the sale, the insider now owns 54,826 shares in the company, valued at $2,288,985.50. This represents a 5.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 15.82% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Blue Trust Inc. raised its holdings in shares of Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after acquiring an additional 270 shares during the last quarter. State of Wyoming purchased a new stake in Kymera Therapeutics in the 4th quarter valued at about $45,000. GF Fund Management CO. LTD. purchased a new stake in Kymera Therapeutics in the 4th quarter valued at about $55,000. Quarry LP purchased a new stake in Kymera Therapeutics in the 3rd quarter valued at about $95,000. Finally, KBC Group NV increased its stake in Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after buying an additional 752 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.